The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $3.19

Today's change0.00 0.00%
Updated February 9 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $3.19

Today's change0.00 0.00%
Updated February 9 4:00 PM -5GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc closed at (U.S.)$3.19.

Over the last five days, shares have lost 7.27% and are down 36.83% for the last year to date. This security has underperformed the S&P 500 by 61.15% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $3.19
  • High--
  • Low--
  • Bid / Ask(U.S.) $3.18 / (U.S.) $3.50
  • YTD % change-36.83%
  • Volume0
  • Average volume (10-day)1,372,278
  • Average volume (1-month)1,512,418
  • Average volume (3-month)2,150,502
  • 52-week range(U.S.) $2.80 to (U.S.) $14.89
  • Beta4.08
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.26
Updated February 9 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1,484.13%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue4311
Total other revenue--------
Total revenue4311
Gross profit1210
Total cost of revenue4110
Total operating expense35292940
Selling / general / administrative20211934
Research & development118106
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-31-27-28-40
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-31-27-28-40
Income after tax-31-27-28-40
Income tax, total0001
Net income-31-27-28-40
Total adjustments to net income--------
Net income before extra. items-31-27-28-40
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-31-27-28-40
Inc. avail. to common incl. extra. items-31-27-28-40
Diluted net income-31-27-28-40
Dilution adjustment--------
Diluted weighted average shares10510510192
Diluted EPS excluding extraordinary itemsvalue per share-0.29-0.26-0.28-0.44
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.29-0.26-0.28-0.44